Company intelligence / Profile preview

Single Technologies

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

Single Technologies is a Swedish biotech tools company developing Theta, a high‑throughput 3‑D Sequencing™ platform for DNA and spatial omics that aims to enable ~$10 whole‑genome sequencing and large‑scale, in‑cell 3D spatial sequencing to support AI‑driven biology, precision medicine and cancer research.

Modalities: Device
Industry: Molecular Diagnostics

Partnerships

Envisioned collaborations with leading academic and medical centers (e.g., Karolinska Institute, Harvard and others mentioned as examples for future “Single centres” early access sites, not formalized named deals yet)Supported and backed by the European Innovation Council (EIC Fund) via EIC Accelerator funding, positioning it within EU deep‑tech/biotech networks

Beyond the preview

Go deeper on Single Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Single Technologies.

Explore the full profile